Metabolic syndrome and diabetes mellitus in COPD

European Respiratory Monograph

Volumn 59, Issue , 2013, Pages 117-134

  Wells, Claire E ^a   Baker, Emma H ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Atherogenesis; Inflammation; Insulin resistance; Lifestyle; Obesity

Indexed keywords

2, 4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ADIPOCYTOKINE; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; CHEMOKINE; CIGARETTE SMOKE; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID; GLITAZONE DERIVATIVE; GLUCOSE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; RAMIPRIL; REACTIVE OXYGEN METABOLITE; SOMATOSTATIN; UNCLASSIFIED DRUG; VITAMIN D;

AEROBIC EXERCISE; ARTICLE; BONE METABOLISM; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITION; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DYSLIPIDEMIA; FOLLOW UP; FRAMINGHAM RISK SCORE; GLUCOSE TOLERANCE; HYPERTENSION; HYPOXIA; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID PEROXIDATION; METABOLIC SYNDROME X; MORTALITY; NEOPLASM; NUTRITION; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PREVALENCE; RESISTANCE TRAINING; RESPIRATORY TRACT DISEASE; RISK FACTOR; SKELETAL MUSCLE;

EID: 84874913001     PISSN: 1025448X     EISSN: 20756674     Source Type: Book Series    
DOI: 10.1183/1025448x.10011912     Document Type: Article

References (151)

1. Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
2. Krebs M, Roden M. Molecular mechanisms of lipid-induced insulin resistance in muscle, liver and vasculature. Diabetes Obes Metab 2005; 7: 621-632.
3. Cornier MA, Dabelea D, Hernandez TL, et al. The metabolic syndrome. Endocr Rev 2008; 29: 777-822.
4. Romeo GR, Lee J, Shoelson SE Metabolic syndrome, insulin resistance, and roles of inflammation-mechanisms and therapeutic targets. Arterioscler Thromb Vasc Biol 2012; 32: 1771-1776.
5. Emanuelli B, Peraldi P, Filloux C, et al. SOCS-3 inhibits insulin signalling and is up-regulated in response to tumor necrosis factor-α in the adipose tissue of obese mice. J Biol Chem 2001; 276: 47944-47949.
6. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat Med 2005; 11: 183-190.
7. Palomo I, Alarcón M, Moore-Carrasco R, et al. Hemostasis alterations in metabolic syndrome. Int J Mol Med 2006; 18: 969-974.
8. Grattagliano I, Palmieri VO, Portincasa P, et al. Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hypothesis. J Nutr Biochem 2008; 19: 491-504.
9. Norris JM, Rich SS. Genetics of glucose homeostasis: implications for insulin resistance and metabolic syndrome. Arterioscler Thromb Vasc Biol 2012; 32: 2091-2096.
10. Iijima K, Iimuro S, Ohashi Y, et al. Lower physical activity, but not excessive calorie intake, is associated with metabolic syndrome in elderly with type 2 diabetes mellitus: The Japanese Elderly Diabetes Intervention Trial. Geriatr Gerontol Int 2012; 12: Suppl. 1, 68-76.
11. Hester EK. HIV medications: an update and review of metabolic complications. Nutr Clin Pract 2012; 27: 51-64.
12. De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2011; 8: 114-126.
13. Carella AM, Antonucci G, Conte M, et al. Antihypertensive treatment with beta-blockers in the metabolic syndrome: a review. Curr Diabetes Rev 2010; 6: 215-221.
14. Chanson P, Salenave S. Metabolic syndrome in Cushing's syndrome. Neuroendocrinol 2010; 92: Suppl. 1, 96-101.
15. Kassi E, Pervanidou P, Kaltsas G, et al. Metabolic syndrome: definitions and controversies. BMC Med 2011; 9: 48.
16. Sumner AD, Khalil YK, Reed JF 3rd. The relationship of peripheral arterial disease and metabolic syndrome prevalence in asymptomatic US adults 40 years and older: results from the National Health and Nutrition Examination Survey (1999-2004). J Clin Hypertens (Greenwich) 2012; 14: 144-148.
17. Chang JJ, Chu CM, Wang PC, et al. Differences in prevalence and severity of coronary artery disease by three metabolic syndrome definitions. Can J Cardiol 2012; 28: 208-214.
18. Rachas A, Raffaitin C, Barberger-Gateau P, et al. Clinical usefulness of the metabolic syndrome for the risk of coronary heart disease does not exceed the sum of its individual components in older men and women. The Three-City (3C) Study. Heart 2012; 98: 650-655.
19. McNeill AM, Rosamond WD, Girman CJ, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005; 28: 385-390.
20. Tziomalos K, Athyros VG, Karagiannis A, et al. Endothelial dysfunction in metabolic syndrome: prevalence, pathogenesis and management. Nutr Metab Cardiovasc Dis 2010; 20: 140-146.
21. Mathieu P, Pibarot P, Després JP. Metabolic syndrome: the danger signal in atherosclerosis. Vasc Health Risk Manag 2006; 2: 285-302.
22. Atlantis E, Martin SA, Haren MT, et al. Inverse associations between muscle mass, strength, and the metabolic syndrome. Metabolism 2009; 58: 1013-1022.
23. Hwang DK, Choi HJ. The relationship between low bone mass and metabolic syndrome in Korean women. Osteoporos Int 2010; 21: 425-431.
24. Chen W, Lu F, Liu SJ, et al. Cancer risk and key components of metabolic syndrome: a population-based prospective cohort study in Chinese. Chin Med J (Engl) 2012; 125: 481-485.
25. Pan A, Keum N, Okereke OI, et al. Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diabetes Care 2012; 35: 1171-1180.
26. Viscogliosi G, Andreozzi P, Chiriac IM, et al. Screening cognition in the elderly with metabolic syndrome. Metab Syndr Relat Disord 2012; 10: 358-362.
27. Vieira JR, Elkind MS, Moon YP, et al. The metabolic syndrome and cognitive performance: the Northern Manhattan Study. Neuroepidemiology 2011; 37: 153-159.
28. World Health Organisation. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: report of a WHO/IDF consultation. 2006 www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf Date last updated: 2006. Date last accessed: January 9, 2013.
29. Lorenzo C, Williams K, Hunt KJ, et al. The National Cholesterol Education Program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 2007; 30: 8-13.
30. Bierman EL. George Lyman Duff Memorial Lecture. Atherogenesis in diabetes. Arterioscler Thromb Vasc Biol 1992; 12: 647-656.
31. Cusi K. The role of adipose tissue and lipotoxicity in the pathogenesis of type 2 diabetes. Curr Diab Rep 2010; 10: 306-315.
32. Grundy SM. Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol 2012; 59: 635-643.
33. Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007; 30: 753-759.
34. Koh GC, Peacock SJ, van der Poll T, et al. The impact of diabetes on the pathogenesis of sepsis. Eur J Clin Microbiol Infect Dis 2012; 31: 379-388.
35. Brennan AL, Gyi KM, Wood DM, et al. Airway glucose concentrations and effect on growth of respiratory pathogens in cystic fibrosis. J Cyst Fibros 2007; 6: 101-109.
36. Brennan AL, Baines DL, Woollhead A, et al. Development of an in vitro model to investigate the effect of glucose on the interaction between respiratory epithelia and bacterial pathogens. Thorax 2006; 61: Suppl. 2, 101.
37. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002; 106: 2067-2072.
38. Park BH, Park MS, Chang J, et al. Chronic obstructive pulmonary disease and metabolic syndrome: a nationwide survey in Korea. Int J Tuberc Lung Dis 2012; 16: 694-700.
39. Minas M, Kostikas K, Papaioannou AI, et al. The association of metabolic syndrome with adipose tissue hormones and insulin resistance in patients with COPD without co-morbidities. COPD 2011; 8: 414-420.
40. Kupeli E, Ulubay G, Ulasli SS, et al. Metabolic syndrome is associated with increased risk of acute exacerbation of COPD: a preliminary study. Endocrine 2010; 38: 76-82.
41. Marquis K, Debigare R, Lacasse Y, et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 809-813.
42. Watz H, Waschki B, Kirsten A, et al. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest 2009; 136: 1039-1046.
43. Poulain M, Doucet M, Drapeau V, et al. Metabolic and inflammatory profile in obese patients with chronic obstructive pulmonary disease. Chron Respir Dis 2008; 5: 35-41.
44. Funakoshi Y, Omori H, Mihara S, et al. Association between airflow obstruction and the metabolic syndrome or its components in Japanese men. Intern Med 2010; 49: 2093-2099.
45. Lam KB, Jordan RE, Jiang CQ, et al. Airflow obstruction and metabolic syndrome: the Guangzhou Biobank Cohort Study. Eur Respir J 2010; 35: 317-323.
46. Chang C, Yao WZ, Fang TS. [Incidence of comorbidities in hospitalized chronic obstructive pulmonary disease patients and correlated risk factors.] Zhonghua Yi Xue Za Zhi 2012; 92: 943-947.
47. Almagro P, López F, Cabrera FJ, et al. [Comorbidities in patients hospitalized due to chronic obstructive pulmonary disease. A comparative analysis of the ECCO and ESMI studies.] Rev Clin Esp 2012; 212: 281-286.
48. Rubinsztajn R, Chazan R. [Mortality and comorbidity in hospitalized chronic obstructive pulmonary disease patients.] Pneumonol Alergol Pol 2011; 79: 343-346.
49. Parappil A, Depczynski B, Collett P, et al. Effect of comorbid diabetes on length of stay and risk of death in patients admitted with acute exacerbations of COPD. Respirology 2010; 15: 918-922.
50. Crisafulli E, Costi S, Luppi F, et al. Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation. Thorax 2008; 63: 487-492.
51. Terzano C, Conti V, Di Stefano F, et al. Comorbidity, hospitalization, and mortality in COPD: results from a longitudinal study. Lung 2010; 188: 321-329.
52. Mapel DW, Dutro MP, Marton JP, et al. Identifying and characterizing COPD patients in US managed care. A retrospective, cross-sectional analysis of administrative claims data. BMC Health Serv Res 2011; 11: 43.
53. Gudmundsson G, Gislason T, Lindberg E, et al. Mortality in COPD patients discharged from hospital: the role of treatment and co-morbidity. Respir Res 2006; 7: 109.
54. Cazzola M, Bettoncelli G, Sessa E, et al. Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration 2010; 80: 112-119.
55. van Manen JG, Bindels PJ, IJzermans CJ, et al. Prevalence of comorbidity in patients with a chronic airway obstruction and controls over the age of 40. J Clin Epidemiol 2001; 54: 287-293.
56. Sidney S, Sorel M, Quesenberry CP Jr, et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005; 128: 2068-2075.
57. Rana JS, Mittleman MA, Sheikh J, et al. Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women. Diabetes Care 2004; 27: 2478-2484.
58. Song Y, Klevak A, Manson JE, et al. Asthma, chronic obstructive pulmonary disease, and type 2 diabetes in the Women's Health Study. Diabetes Res Clin Pract 2010; 90: 365-371.
59. Mannino DM, Thorn D, Swensen A, et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32: 962-969.
60. Joo H, Park J, Lee SD, et al. Comorbidities of chronic obstructive pulmonary disease in Koreans: a population-based study. J Korean Med Sci 2012; 27: 901-906.
61. Feary JR, Rodrigues LC, Smith CJ, et al. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010; 65: 956-962.
62. Steuten LM, Creutzberg EC, Vrijhoef HJ, et al. COPD as a multicomponent disease: inventory of dyspnoea, underweight, obesity and fat free mass depletion in primary care. Prim Care Respir J 2006; 15: 84-91.
63. Schokker DF, Visscher TL, Nooyens AC, et al. Prevalence of overweight and obesity in the Netherlands. Obes Rev 2007; 8: 101-108.
64. Eisner MD, Blanc PD, Sidney S, et al. Body composition and functional limitation in COPD. Respir Res 2007; 8: 7.
65. Centers for Disease Control and Prevention (CDC). Behavioral Risk Factor Surveillance System Survey Data. Atlanta, US Department of Health and Human Services, Centers for Disease Control and Prevention 2012. Available from http://www.cdc.gov/brfss/.
66. Skyba P, Ukropec J, Pobeha P, et al. Metabolic phenotype and adipose tissue inflammation in patients with chronic obstructive pulmonary disease. Mediators Inflamm 2010; 2010: 173498.
67. Vorrink SN, Kort HS, Troosters T, et al. Level of daily physical activity in individuals with COPD compared with healthy controls. Respir Res 2011; 12: 33.
68. Coronado M, Janssens JP, de Muralt B, et al. Walking activity measured by accelerometry during respiratory rehabilitation. J Cardiopulm Rehabil 2003; 23: 357-364.
69. Canoy D, Wareham N, Luben R, et al. Cigarette smoking and fat distribution in 21,828 British men and women: a population-based study. Obes Res 2005; 13: 1466-1475.
70. Attvall S, Fowelin J, Lager I, et al. Smoking induces insulin resistance-a potential link with the insulin resistance syndrome. J Intern Med 1993; 233: 327-332.
71. Facchini FS, Hollenbeck CB, Jeppesen J, et al. Insulin resistance and cigarette smoking. Lancet 1992; 339: 1128-1130.
72. Eliasson B, Attvall S, Taskinen MR, et al. The insulin resistance syndrome in smokers is related to smoking habits. Arterioscler Thromb Vasc Biol 1994; 14: 1946-1950.
73. Weitzman M, Cook S, Auinger P, et al. Tobacco smoke exposure is associated with the metabolic syndrome in adolescents. Circulation 2005; 112: 862-869.
74. Manson JE, Ajani UA, Liu S, et al. A prospective study of cigarette smoking and the incidence of diabetes mellitus among U.S. male physicians. Am J Med 2000; 109: 538-542.
75. Eliasson B, Attvall S, Taskinen MR, et al. Smoking cessation improves insulin sensitivity in healthy middle-aged men. Eur J Clin Invest 1997; 27: 450-456.
76. Walters JA, Gibson PG, Wood-Baker R, et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2009; 1: CD001288.
77. Walters JAE, Walters EH, Wood-Baker R. Oral corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; 3: CD005374.
78. Slatore CG, Bryson CL, Au DH. The association of inhaled corticosteroid use with serum glucose concentration in a large cohort. Am J Med 2009; 122: 472-478.
79. Faul JL, Wilson SR, Chu JW, et al. The effect of an inhaled corticosteroid on glucose control in type 2 diabetes. Clin Med Res 2009; 7: 14-20.
80. Pauwels RA, Löfdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999; 340: 1948-1953.
81. Stanciu S, Marinescu R, Iordache M, et al. Are systemic inflammatory profiles different in patients with COPD and metabolic syndrome as compared to those with COPD alone? Respir Res 2006; 7: 109.
82. Takahashi H, Iizuka H. Psoriasis and metabolic syndrome. J Dermatol 2012; 39: 212-218.
83. Santos MJ, Fonseca JE. Metabolic syndrome, inflammation and atherosclerosis - the role of adipokines in health and in systemic inflammatory rheumatic diseases. Acta Reumatol Port 2009; 34: 590-598.
84. Stagakis I, Bertsias G, Karvounaris S, et al. Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther 2012; 14: R141.
85. Rahman I, Morrison D, Donaldson K, et al. Systemic oxidative stress in asthma, COPD, and smokers. Am J Respir Crit Care Med 1996; 154: 1055-1060.
86. Chung KF, Adcock IM. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J 2008; 31: 1334-1356.
87. Ge RL, Simonson TS, Cooksey RC, et al. Metabolic insight into mechanisms of high-altitude adaptation in Tibetans. Mol Genet Metab 2012; 106: 244-247.
88. Sauerwein HP, Schols AM. Glucose metabolism in chronic lung disease. Clin Nutr. 2002; 21: 367-371.
89. Gamboa JL, Garcia-Cazarin ML, Andrade FH. Chronic hypoxia increases insulin-stimulated glucose uptake in mouse soleus muscle. Am J Physiol Regul Integr Comp Physiol 2011; 300: R85-R91.
90. Castillo O, Woolcott OO, Gonzales E, et al. Residents at high altitude show a lower glucose profile than sea-level residents throughout 12-hour blood continuous monitoring. High Alt Med Biol 2007; 8: 307-311.
91. de Mol P, Fokkert MJ, de Vries ST, et al. Metabolic effects of high altitude trekking in patients with type 2 diabetes. Diabetes Care 2012; 35: 2018-2020.
92. Schobersberger W, Schmid P, Lechleitner M, et al. Austrian Moderate Altitude Study 2000 (AMAS 2000). The effects of moderate altitude (1,700 m) on cardiovascular and metabolic variables in patients with metabolic syndrome. Eur J Appl Physiol 2003; 88: 506-514.
93. Baracco R, Mohanna S, Seclén S. A comparison of the prevalence of metabolic syndrome and its components in high and low altitude populations in Peru. Metab Syndr Relat Disord 2007; 5: 55-62.
94. Hjalmarsen A, Aasebø U, Birkeland K, et al. Impaired glucose tolerance in patients with chronic hypoxic pulmonary disease. Diabetes Metab 1996; 22: 37-42.
95. Jakobsson P, Jorfeldt L, von Schenck H. Fat metabolism and its response to infusion of insulin and glucose in patients with advanced chronic obstructive pulmonary disease. Clin Physiol 1995; 15: 319-329.
96. Jakobsson P, Jorfeldt L. Oxygen supplementation increases glucose tolerance during euglycaemic hyperinsulinaemic glucose clamp procedure in patients with severe COPD and chronic hypoxaemia. Clin Physiol Funct Imaging 2006; 26: 271-274.
97. Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S, Thompson A et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364: 829-841.
98. Yeh F, Dixon AE, Marion S, et al. Obesity in adults is associated with reduced lung function in metabolic syndrome and diabetes: the Strong Heart Study. Diabetes Care 2011; 34: 2306-2313.
99. Lessard A, Alméras N, Turcotte H, et al. Adiposity and pulmonary function: relationship with body fat distribution and systemic inflammation. Clin Invest Med 2011; 34: E64-E70.
100. Mori H, Okubo M, Okamura M, et al. Abnormalities of pulmonary function in patients with non-insulin-dependent diabetes mellitus. Intern Med 1992; 31: 189-193.
101. Weynand B, Jonckheere A, Frans A, et al. Diabetes mellitus induces a thickening of the pulmonary basal lamina. Respiration 1999; 66: 12-13.
102. Loukides S, Polyzogopoulos D. The effect of diabetes mellitus on the outcome of patients with chronic obstructive pulmonary disease exacerbated due to respiratory infections. Respiration 1996; 63: 170-173.
103. Baker EH, Janaway CH, Philips BJ, et al. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax 2006; 61: 284-289.
104. Chakrabarti B, Angus RM, Agarwal S, et al. Hyperglycaemia as a predictor of outcome during non-invasive ventilation in decompensated COPD. Thorax 2009; 64: 857-862.
105. Archer JRH, Baker EH. Diabetes and metabolic dysfunction in COPD. Respiratory Medicine: COPD Update 2009; 5: 67-74.
106. Cazzola M, Calzetta L, Rogliani P, et al. High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway. Am J Respir Cell Mol Biol 2012; 47: 509-516.
107. Seymour JM, Spruit MA, Hopkinson NS, et al. The prevalence of quadriceps weakness in COPD and the relationship with disease severity. Eur Respir J 2010; 36: 81-88.
108. Hopkinson NS, Tennant RC, Dayer MJ, et al. A prospective study of decline in fat free mass and skeletal muscle strength in chronic obstructive pulmonary disease. Respir Res 2007; 8: 25-32.
109. Swallow EB, Reyes D, Hopkinson NS, et al. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax 2007; 62: 115-120.
110. Decramer M, Gosselink R, Troosters T, et al. Muscle weakness is related to utilization of health care resources in COPD patients. Eur Respir J 1997; 10: 417-423.
111. Garcia-Aymerich J, Félez MA, Escarrabill J, et al. Physical activity and its determinants in severe chronic obstructive pulmonary disease. Med Sci Sports Exerc 2004; 36: 1667-1673.
112. Park SW, Goodpaster BH, Strotmeyer ES, et al. Decreased muscle strength and quality in older adults with type 2 diabetes: the Health, Aging and Body Composition Study. Diabetes 2006; 55: 1813-1818.
113. Park SW, Goodpaster BH, Strotmeyer ES, et al. Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: the Health, Aging, and Body Composition study. Diabetes Care 2007; 30: 1507-1512.
114. Gregg EW, Beckles GL, Williamson DF, et al. Diabetes and physical disability among U.S. adults. Diabetes Care 2000; 23: 1272-1277.
115. Miller DK, Lui LY, Perry HM 3rd, et al. Reported and measured physical functioning in older inner-city diabetic African Americans. J Gerontol A Biol Sci Med Sci 1999; 54: M230-M236.
116. Boirie Y, Short KR, Ahlman B, et al. Tissue-specific regulation of mitochondrial and cytoplasmic protein synthesis rates by insulin. Diabetes 2001; 50: 2652-2658.
117. Siew ED, Pupim LB, Majchrzak KM, et al. Insulin resistance is associated with skeletal muscle protein breakdown in non-diabetic chronic hemodialysis patients. Kidney Int 2007; 71: 146-152.
118. Bierbrauer J, Weber-Carstens S. [Insulin resistance and protein catabolism in critically ill patients.] Anasthesiol Intensivmed Notfallmed Schmerzther 2011; 46: 268-274.
119. Stump CS, Short KR, Bigelow ML, et al. Effect of insulin on human skeletal muscle mitochondrial ATP production, protein synthesis, and mRNA transcripts. Proc Natl Acad Sci USA 2003; 100: 7996-8001.
120. Kelley DE, He J, Menshikova EV, et al. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 2002; 51: 2944-2950.
121. Schnell K, Weiss CO, Lee T, et al. The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999-2008. BMC Pulm Med 2012; 12: 26.
122. Graat-Verboom L, Smeenk FW, van den Borne BE, et al. Progression of osteoporosis in patients with COPD: a 3-year follow up study. Respir Med 2012; 106: 861-870.
123. McFarlane SI. Bone metabolism and the cardiometabolic syndrome: pathophysiologic insights. J Cardiometab Syndr 2006; 1: 53-57.
124. Romme EA, Rutten EP, Smeenk FW, et al. Vitamin D status is associated with bone mineral density and functional exercise capacity in patients with chronic obstructive pulmonary disease. Ann Med 2012; [Epub ahead of print DOI: 10.3109/07853890.2012.671536].
125. Boucher BJ. Is vitamin D status relevant to metabolic syndrome? Dermatoendocrinol 2012; 4: 212-224.
126. Rodríguez-Roisin R, Soriano JB. Chronic obstructive pulmonary disease with lung cancer and/or cardiovascular disease. Proc Am Thorac Soc 2008; 5: 842-847.
127. Dodd JW, Getov SV, Jones PW. Cognitive function in COPD. Eur Respir J 2010; 35: 913-922.
128. Viscogliosi G, Andreozzi P, Chiriac IM, et al. Depressive symptoms in older people with metabolic syndrome: is there a relationship with inflammation? Int J Geriatr Psychiatry 2012; [Epub ahead of print; DOI: 10.1002/gps.3817].
129. Sepanjnia K, Modabbernia A, Ashrafi M, et al. Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial. Neuropsychopharmacology 2012; 37: 2093-2100.
130. Katsumata Y, Todoriki H, Higashiuesato Y, et al. Metabolic syndrome and cognitive decline among the oldest old in Okinawa: in search of a mechanism. The KOCOA Project. J Gerontol A Biol Sci Med Sci 2012; 67: 126-134.
131. Reijmer YD, van den Berg E, Dekker JM, et al. The metabolic syndrome, atherosclerosis and cognitive functioning in a non-demented population: the Hoorn Study. Atherosclerosis 2011; 219: 839-845.
132. McEvoy LK, Laughlin GA, Barrett-Connor E, et al. Metabolic syndrome and 16-year cognitive decline in community-dwelling older adults. Ann Epidemiol 2012; 22: 310-317.
133. US Department of Health and Human Services. Agency for Healthcare Research and quality. National Quality Measures Clearinghouse. Guideline Synthesis: Chronic Obstructive Pulmonary Disease (COPD): Pulmonary Rehabilitation. Last updated December 2011. www.qualitymeasures.ahrq.gov/syntheses/synthesis.aspx?id535091 Date last updated: December 2011 Date last accessed: January 9, 2013.
134. Healy GN, Matthews CE, Dunstan DW, et al. Sedentary time and cardio-metabolic biomarkers in US adults: NHANES 2003-06. Eur Heart J 2011; 32: 590-597.
135. Hwang CL, Wu YT, Chou CH. Effect of aerobic interval training on exercise capacity and metabolic risk factors in people with cardiometabolic disorders. J Cardiopulm Rehabil Prev 2011; 31: 378-385.
136. Schjerve IE, Tyldum GA, Tjønna AE, et al. Both aerobic endurance and strength training programmes improve cardiovascular health in obese adults. Clin Sci (Lond) 2008; 115: 283-293.
137. Tjonna AE, Lee SJ, Rognmo O, et al. Aerobic interval training versus continuous moderate exercise as a treatment for the metabolic syndrome: a pilot study. Circulation 2008; 118: 346-354.
138. Bweir S, Al-Jarrah M, Almalty AM, et al. Resistance exercise training lowers HbA1c more than aerobic training in adults with type 2 diabetes. Diabetol Metab Syndr 2009; 1: 27.
139. Tambalis K, Panagiotakos DB, Kavouras SA, et al. Responses of blood lipids to aerobic, resistance, and combined aerobic with resistance exercise training: a systematic review of current evidence. Angiology 2009; 60: 614-632.
140. Pitsavos C, Panagiotakos DB, Tambalis KD, et al. Resistance exercise plus to aerobic activities is associated with better lipids' profile among healthy individuals: the ATTICA study. QJM 2009; 102: 609-616.
141. Athyros VG, Tziomalos K, Karagiannis A, et al. Cardiovascular benefits of bariatric surgery in morbidly obese patients. Obes Rev 2011; 12: 515-512.
142. Landbo C, Prescott E, Lange P, et al. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 1856-1861.
143. Minehira K, Tappy L. Dietary and lifestyle interventions in the management of the metabolic syndrome: present status and future perspective. Eur J Clin Nut 2002; 56: 1264-1269.
144. Visioli F. Nutritional support in the pharmacological treatment of metabolic syndrome. Eur J Pharmacol 2011; 668: Suppl. 1, S43-S49.
145. Pour OR, Dagogo-Jack S. Prediabetes as a therapeutic target. Clin Chem 2011; 57: 215-220.
146. Ajjan RA, Grant PJ. Cardiovascular disease prevention in patients with type 2 diabetes: The role of oral antidiabetic agents. Diab Vasc Dis Res 2006; 3: 147-158.
147. Bailey CJ. Metformin: effects on micro and macrovascular complications in type 2 diabetes mellitus. Cardiovasc Drugs Ther 2008; 22: 215-224.
148. Lardizabal JA, Deedwania PC. The role of renin-angiotensin agents in altering the natural history of type 2 diabetes mellitus. Curr Cardiol Rep 2010; 12: 464-471.
149. Putnam K, Shoemaker R, Yiannikouris F, et al. The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. Am J Physiol Heart Circ Physiol 2012; 302: H1219-H1230.
150. Perk J, De Backer G, Gohlke H, et al. The fifth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J 2012; 33: 1635-1701.
151. Mills EJ, Wu P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM 2011; 104: 109-124.